Government-Owned Inventions; Availability for Licensing, 61717-61719 [2011-25730]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 193 / Wednesday, October 5, 2011 / Notices
product that disrupts a Notch signaling
pathway. Nat Genet. 2003
Feb;33(2):208–213. [PMID 12539049]
2. Martins C, et al. A study of
MECT1–MAML2 in mucoepidermoid
carcinoma and Warthin’s tumor of
salivary glands. J Mol Diagn. 2004
Aug;6(3):205–210. [PMID 15269296]
3. Coxon A, et al. Mect1–Maml2
fusion oncogene linked to the aberrant
activation of cyclic AMP/CREB
regulated genes. Cancer Res. 2005 Aug
15;65(16):7137–7144. [PMID 16103063]
4. Komiya T, et al. Sustained
expression of Mect1–Maml2 is essential
for tumor cell growth in salivary gland
cancers carrying the t(11;19)
translocation. Oncogene. 2006 Oct
5;25(45):6128–6132. [PMID 16652146]
5. Kaye FJ. Emerging biology of
malignant salivary gland tumors offers
new insights into the classification and
treatment of mucoepidermoid cancer.
Clin Cancer Res. 2006 Jul 1;12(13):3878–
3881. [PMID 16818681]
6. Tirado Y, et al. CRTC1/MAML2
fusion transcript in high grade
mucoepidermoid carcinomas of salivary
and thyroid glands and Warthin’s
tumors: implications for histogenesis
and biologic behavior. Genes
Chromosomes Cancer. 2007
Jul;46(7):708–715. [PMID 17437281]
7. Komiya T, et al. Enhanced activity
of the CREB co-activator Crtc1 in LKB1
null lung cancer. Oncogene. 2010 Mar
18;29(11):1672–1680. [PMID 20010869]
Intellectual Property: HHS, Reference
No. E–086–2003/0 —
• U.S. Patent No. 7,553,822 issued 30
June 2009
• U.S. Patent Application No. 12/
493,901 filed 29 June 2009
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560;
mccuepat@mail.nih.gov
Dated: September 29, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–25734 Filed 10–4–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
SUMMARY:
VerDate Mar<15>2010
19:11 Oct 04, 2011
Jkt 226001
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Humanized Monoclonal Antibodies
Efficient for Neutralization of TickBorne Encephalitis Virus (TBEV)
Description of Technology: TBEV
causes serious illnesses from meningitis
to meningo-encephalitis, totaling 3,000
cases of hospitalization in Europe and
between 5,000–10,000 cases in Russia
reported every year. The Far Eastern
hemorrhagic TBEV strains are
associated with a mortality rate
(between 1–2%), higher than other
strains isolated in the Siberia or Western
Europe. There is a high proportion (up
to 46%) of TBEV patients with
temporary or permanent neurological
sequelae. The number of TBEV
infections has increased steadily and
TBEV cases have been reported in new
areas, probably reflecting an increased
spread of vector tick species. Prevention
of TBEV infections has been carried out
in a few countries in Europe by
immunization using an inactivated
TBEV vaccine. The vaccine carries a
high manufacturing cost and requires a
regimen of multiple doses, and for this
reason, vaccination is not generally
carried out. The materials disclosed are
humanized monoclonal antibodies
derived from TBEV-neutralizing Fab
antibodies isolated from infected
chimpanzees by repertoire cloning. One
antibody in particular, MAb 2E6, has
been demonstrated to bind to and
neutralize a TBEV/dengue type 4 virus
chimera (via interaction with the TBEV
antigenic determinants) as well as the
related Langat virus. Protection against
TBEV/DEN–4 infection and Langat
infection has been demonstrated using
animal models of infection. The
antibodies disclosed, in particular MAb
2E6, have the potential for use as
prophylactic and therapeutic agents
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
61717
against TBEV and Langat virus.
Additionally, these antibodies may be
suitable as diagnostic reagents for the
detection of TBEV and/or Langat virus.
Potential Commercial Applications:
• TBEV Prophylaxis.
• TBEV Therapy.
• TBEV Diagnostics.
Competitive Advantages:
• Cost effective alternative to existing
vaccine.
• Fully humanized antibody.
• Strongly neutralizing antibody.
• Efficient production methods.
Development Stage:
• Pre-clinical.
• In vitro data available.
• In vivo data available (animal).
Inventors: C. J. Lai, Robert Purcell,
Alexander Pletnev (NIAID).
Intellectual Property: HHS Reference
No. E–231–2011/0—Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Peter Soukas; 301–
435–4646; soukasp@mail.nih.gov
Collaborative Research Opportunity:
The NIAID is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize TBEV monoclonal
antibodies. For collaboration
opportunities, please contact Wade
Williams at 301–827–0258.
Rapid Molecular Assays for Specific
Detection and Quantitation of Loa Loa
Microfilaremia
Description of Technology: The risk of
fatal reactions in some infected
individuals administered drug
treatments for Loa loa infection, and the
lack of accurate, convenient, diagnostics
for this infection have thwarted efforts
to eradicate the disease. Time
consuming, labor intensive and training
intensive microscope-based analysis of
blood samples is the standard available
diagnostic for Loa loa infection. This
new assay technology introduces an
easy to use, species-specific, highly
sensitive, diagnostic that is able to be
performed with minimal training.
Positive test results may be indicated by
an easily visualized color change and
this test may be run without the need
for expensive equipment such as a
thermocycler. Because this test is rapid,
cost efficient, labor efficient, accurate,
and simple to run and read, it may be
readily incorporated into portable pointof-care formats. These attributes make it
ideally suited for use in locations where
Loa loa infection is endemic. These
advantages may lead to this technology
becoming the new standard for
diagnosis of Loa loa infections and a
valuable tool, in control programs, to
E:\FR\FM\05OCN1.SGM
05OCN1
61718
Federal Register / Vol. 76, No. 193 / Wednesday, October 5, 2011 / Notices
identify risks for adverse treatment
reactions.
Potential Commercial Applications:
• Diagnostics testing.
• Infectious disease monitoring.
Competitive Advantages: Greater
speed cost and labor efficiencies,
accurate, and simple to run and read
and ability to be incorporated into
portable point-of-care format, ideally
suited for Loa loa endemic regions.
Development Stage:
• Early-stage.
• Pre-clinical.
Inventors: Doran Fink and Thomas
Nutman (NIAID).
Publications:
1. Fink DL, et al. Rapid molecular
assays for specific detection and
quantitation of Loa loa microfilaremia.
PLoS Negl Trop Dis. 2011 Aug 30; 5(8):
e1299; doi:10.1371/
journal.pntd.0001299.
2. Klion AD, et al. Cloning and
characterization of a species-specific
repetitive DNA sequence from Loa loa.
Mol Biochem Parasitol. 1991 Apr; 45(2):
297–305. [PMID: 2038361].
Intellectual Property: HHS Reference
No. E–014–2011/0—U.S. Application
No. 61/410,232 filed 04 Nov 2010.
Related Technologies:
• HHS Reference No. E–281–2010/
0—U.S. Application No. 61/410,239
filed 04 Nov 2010.
• HHS Reference No. E–084–2010/
0—PCT Application No. PCT/US2011/
023320 filed 01 Feb 2011.
Licensing Contact: Tedd Fenn; 301–
435–5031; Tedd.Fenn@nih.gov
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Disease (NIAID) is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize Rapid Molecular Assays
for Specific Detection and Quantitation
of Loa Loa Microfilaremia. For
collaboration opportunities, please
contact Johanna Schneider, PhD. at
Schneiderjs@niaid.nih.gov or 301–451–
9824.
mstockstill on DSK4VPTVN1PROD with NOTICES
Diagnostic Assays and Methods of Use
for Detection of Filarial Infection
Description of Technology: The effort
targeting the mosquito borne neglected
tropical disease lymphatic filariasis for
elimination through mass drug
administration by 2020 will require
accurate, cost effective methods for
detecting early infections. The World
Health Organization-recommended
immunochromatographic test detects
adult Wuchereria bancrofti (Wb) antigen
in blood, but shows variable efficacy
due to the complex life cycle of the
parasites and cross reactivity with other
VerDate Mar<15>2010
19:11 Oct 04, 2011
Jkt 226001
organisms. This variability may hinder
effective lymphatic filariasis elimination
efforts. This new technology improves
available detection methods through use
of an isolated immunoreactive antigen,
Wb123, from infective stage larvae (L3)
Wb; which results in specific detection
early in the infective cycle with reduced
cross reactivity. This technology may
see wide application in testing and
surveillance of lymphatic filariasis as
part of the effort to eliminate the disease
worldwide.
Potential Commercial Applications:
• Diagnostics testing.
• Infectious disease monitoring.
Competitive Advantages: Improved
detection of early stage lymphatic
filariasis.
Development Stage:
• Early-stage.
• Pre-clinical.
Inventors: Doran Fink (NIAID), Joseph
Kubofcik (NIAID), Peter Burbelo
(NIDCR), Thomas Nutman (NIAID).
Publications:
1. Senbagavalli P, et al. Heightened
measures of immune complex and
complement function and immune
complex-mediated granulocyte
activation in human lymphatic
filariasis. Am J Trop Med Hyg. 2011
Jul;85(1):89–96. [PMID 21734131]
2. Bennuru S, et al. Stage-specific
proteomic expression patterns of the
human filarial parasite Brugia malayi
and its endosymbiont Wolbachia. Proc
Natl Acad Sci USA. 2011 Jun;7;108
(23):9649–9654. [PMID 21606368].
3. Steel C, et al. PLoS One. Altered T
cell memory and effector cell
development in chronic lymphatic
filarial infection that is independent of
persistent parasite antigen. 2011 Apr
29;6(4):e19197. [PMID 21559422].
4. Fink DL, et al. Toward molecular
parasitologic diagnosis: enhanced
diagnostic sensitivity for filarial
infections in mobile populations. J Clin
Microbiol. 2011 Jan;49(1):42–47. [PMID
20980560].
5. Bennuru S, et al. Elevated levels of
plasma angiogenic factors are associated
with human lymphatic filarial
infections. Am J Trop Med Hyg. 2010
Oct;83(4):884–890. [PMID 20889885].
Intellectual Property: HHS Reference
No. E–281–2010/0—U.S. Application
No. 61/410,239 filed 04 Nov 2010.
Related Technologies:
• HHS Reference No. E–084–2010/
0—PCT Application No. PCT/US2011/
023320 filed 01 Feb 2011.
• HHS Reference No. E–014–2011/
0—U.S. Application No. 61/410,232
filed 04 Nov 2010.
Licensing Contact: Tedd Fenn; 301–
435–5031; Tedd.Fenn@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Infectious Disease (NIAID) is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize Diagnostic Assays and
Methods of Use for Detection of Filarial
Infection. For collaboration
opportunities, please contact Johanna
Schneider, Ph.D. at
Schneiderjs@niaid.nih.gov or 301–451–
9824.
A System and Method for Detecting
Untoward Events in Hospitals
Description of Technology: This
invention is of potential benefit to
public health and patient care and can
be commercially utilized by medical
centers, hospitals and commercial
developers of hospital information
systems. It is basically a computer
science based technology that may
provide the capability of detecting
untoward events such as patient crises,
individual clinic adverse occurrences
and adverse reactions related to new
medication lots and inconsistencies in
ordered and delivered patient
medications and other treatments. The
technology is comprised of a dedicated
computer server that executes specially
designed software with input data from
a main hospital information system and
other relevant patient data sensors and
systems. The technology also includes
design specifications for constructing a
‘‘patient registration system’’, an
untoward event specification catalogue,
intelligent software for detecting
untoward events, and a report listing
untoward alerts, as well as a light and
sound panel design for signaling
untoward alerts. The preferred
embodiment for this technology is the
NIH Clinical Center Clinical Research
Informatics System (CRIS) presently
operational in the NIH Clinical Center
in Bethesda, Maryland.
Potential Commercial Applications:
The technology can be commercially
utilized by medical centers, hospitals
and commercial developers of hospital
information centers to improve patient
medical treatment and clinical outcome.
Competitive Advantages: The design
of the system is novel and practical. It
fulfills and automates the need for a
system and methodology that predicts,
detects and signals untoward patient
events and other untoward clinical
events.
Development Stage: Prototype.
Inventors: James M. DeLeo and
Patricia P. Sengstack (NIHCC).
Publications:
1. Heldt T, et al. Integrating Data,
Models, and Reasoning in Critical Care.
Proceedings of the 28th IEEE EMBS
Annual International Conference, New
E:\FR\FM\05OCN1.SGM
05OCN1
Federal Register / Vol. 76, No. 193 / Wednesday, October 5, 2011 / Notices
York City, USA, Aug 30–Sept 3, 2006,
pp 350–353; doi 10.1109/
IEMBS.2006.259734.
2. Hripcsak G, et al. Mining complex
clinical data for patient safety research:
a framework for event discovery. J
Biomed Inform. 2003 Feb–Apr;36(1–
2):120–130. [PMID 14552853].
3. Horsky J, et al. A framework for
analyzing the cognitive complexity of
computer assisted clinical ordering. J
Biomed Inform. 2003 Feb–Apr;36(1–
2):4–22. [PMID 14552843].
Intellectual Property: HHS Reference
No. E–227–2009/0—Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: September 26, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–25730 Filed 10–4–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group, Developmental Biology
Subcommittee.
Date: October 20–21, 2011.
Time: 8:30 a.m .to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The River Inn, 924 25th Street, NW.,
Washington, DC 20037.
Contact Person: Cathy J. Wedeen, PhD,
Scientific Review Officer, Division of
Scientific Review, OD Eunice Kennedy
Shriver National Institute of Child Health
VerDate Mar<15>2010
19:11 Oct 04, 2011
Jkt 226001
61719
and Human Development, NIH, 6100
Executive Blvd., Room 5B01–G, Bethesda,
MD 20892, 301–435–6878,
wedeenc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
neidl.od.nih.gov/. For additional
information concerning this meeting,
contact Ms. Kelly Fennington, Senior
Health Policy Analyst, Office of
Biotechnology Activities, Office of
Science Policy, Office of the Director,
National Institutes of Health, 6705
Rockledge Drive, Room 750, Bethesda,
MD 20892–7985; telephone 301–496–
9838; e-mail fennington@nih.gov.
Dated: September 28, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Dated: September 27, 2011.
Amy P. Patterson,
Director, Office of Science Policy, National
Institutes of Health.
[FR Doc. 2011–25633 Filed 10–4–11; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2011–25733 Filed 10–4–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Notice of a meeting of a working group
of the NIH Blue Ribbon Panel
The purpose of this notice is to inform
the public about a meeting of the NIH
Blue Ribbon Panel to Advise on the Risk
Assessment of the National Emerging
Infectious Diseases Laboratories at
Boston University Medical Center.
The meeting will be held Wednesday,
November 2, 2011, at the Hyatt Regency
Bethesda, 7400 Wisconsin Avenue,
Bethesda, MD 20814 from
approximately 8:30 a.m. to 4:30 p.m.
This meeting is the fourth in a series
of public meetings to review and
discuss the ongoing supplementary risk
assessment study being conducted for
the Boston University NEIDL. The
National Research Council Committee
on Technical Input will participate in
this discussion and provide its views.
Public comment will begin at
approximately 4 p.m. In the event that
time does not allow for all those
interested to present oral comments,
anyone may file written comments by
sending them to the address below.
Comments should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the commenter.
The meeting will be open to the
public, with attendance limited to space
available. There will be a live webcast
of the meeting which can be accessed at
https://nihblueribbonpanel-bumcneidl.od.nih.gov/. Individuals who plan
to attend and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the Contact Person listed
below in advance of the meeting.
A draft agenda and slides for the
meeting may be obtained by connecting
to https://nihblueribbonpanel-bumc-
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, ‘‘Investigator Initiated
Program Project Application.’’
Date: October 26, 2011.
Time: 11 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Michelle M Timmerman,
PhD, Scientific Review Officer, Scientific
Review Program, NIH/NIAID/DHHS, Room
3123, 6700B Rockledge Drive, MSC–7616,
Bethesda, MD 20892–7616, (301) 451–4573,
timmermanm@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
E:\FR\FM\05OCN1.SGM
05OCN1
]]>Agencies
[Federal Register Volume 76, Number 193 (Wednesday, October 5, 2011)]
[Notices]
[Pages 61717-61719]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-25730]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Humanized Monoclonal Antibodies Efficient for Neutralization of Tick-
Borne Encephalitis Virus (TBEV)
Description of Technology: TBEV causes serious illnesses from
meningitis to meningo-encephalitis, totaling 3,000 cases of
hospitalization in Europe and between 5,000-10,000 cases in Russia
reported every year. The Far Eastern hemorrhagic TBEV strains are
associated with a mortality rate (between 1-2%), higher than other
strains isolated in the Siberia or Western Europe. There is a high
proportion (up to 46%) of TBEV patients with temporary or permanent
neurological sequelae. The number of TBEV infections has increased
steadily and TBEV cases have been reported in new areas, probably
reflecting an increased spread of vector tick species. Prevention of
TBEV infections has been carried out in a few countries in Europe by
immunization using an inactivated TBEV vaccine. The vaccine carries a
high manufacturing cost and requires a regimen of multiple doses, and
for this reason, vaccination is not generally carried out. The
materials disclosed are humanized monoclonal antibodies derived from
TBEV-neutralizing Fab antibodies isolated from infected chimpanzees by
repertoire cloning. One antibody in particular, MAb 2E6, has been
demonstrated to bind to and neutralize a TBEV/dengue type 4 virus
chimera (via interaction with the TBEV antigenic determinants) as well
as the related Langat virus. Protection against TBEV/DEN-4 infection
and Langat infection has been demonstrated using animal models of
infection. The antibodies disclosed, in particular MAb 2E6, have the
potential for use as prophylactic and therapeutic agents against TBEV
and Langat virus. Additionally, these antibodies may be suitable as
diagnostic reagents for the detection of TBEV and/or Langat virus.
Potential Commercial Applications:
TBEV Prophylaxis.
TBEV Therapy.
TBEV Diagnostics.
Competitive Advantages:
Cost effective alternative to existing vaccine.
Fully humanized antibody.
Strongly neutralizing antibody.
Efficient production methods.
Development Stage:
Pre-clinical.
In vitro data available.
In vivo data available (animal).
Inventors: C. J. Lai, Robert Purcell, Alexander Pletnev (NIAID).
Intellectual Property: HHS Reference No. E-231-2011/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Peter Soukas; 301-435-4646; soukasp@mail.nih.gov
Collaborative Research Opportunity: The NIAID is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize TBEV monoclonal
antibodies. For collaboration opportunities, please contact Wade
Williams at 301-827-0258.
Rapid Molecular Assays for Specific Detection and Quantitation of Loa
Loa Microfilaremia
Description of Technology: The risk of fatal reactions in some
infected individuals administered drug treatments for Loa loa
infection, and the lack of accurate, convenient, diagnostics for this
infection have thwarted efforts to eradicate the disease. Time
consuming, labor intensive and training intensive microscope-based
analysis of blood samples is the standard available diagnostic for Loa
loa infection. This new assay technology introduces an easy to use,
species-specific, highly sensitive, diagnostic that is able to be
performed with minimal training. Positive test results may be indicated
by an easily visualized color change and this test may be run without
the need for expensive equipment such as a thermocycler. Because this
test is rapid, cost efficient, labor efficient, accurate, and simple to
run and read, it may be readily incorporated into portable point-of-
care formats. These attributes make it ideally suited for use in
locations where Loa loa infection is endemic. These advantages may lead
to this technology becoming the new standard for diagnosis of Loa loa
infections and a valuable tool, in control programs, to
[[Page 61718]]
identify risks for adverse treatment reactions.
Potential Commercial Applications:
Diagnostics testing.
Infectious disease monitoring.
Competitive Advantages: Greater speed cost and labor efficiencies,
accurate, and simple to run and read and ability to be incorporated
into portable point-of-care format, ideally suited for Loa loa endemic
regions.
Development Stage:
Early-stage.
Pre-clinical.
Inventors: Doran Fink and Thomas Nutman (NIAID).
Publications:
1. Fink DL, et al. Rapid molecular assays for specific detection
and quantitation of Loa loa microfilaremia. PLoS Negl Trop Dis. 2011
Aug 30; 5(8): e1299; doi:10.1371/journal.pntd.0001299.
2. Klion AD, et al. Cloning and characterization of a species-
specific repetitive DNA sequence from Loa loa. Mol Biochem Parasitol.
1991 Apr; 45(2): 297-305. [PMID: 2038361].
Intellectual Property: HHS Reference No. E-014-2011/0--U.S.
Application No. 61/410,232 filed 04 Nov 2010.
Related Technologies:
HHS Reference No. E-281-2010/0--U.S. Application No. 61/
410,239 filed 04 Nov 2010.
HHS Reference No. E-084-2010/0--PCT Application No. PCT/
US2011/023320 filed 01 Feb 2011.
Licensing Contact: Tedd Fenn; 301-435-5031; Tedd.Fenn@nih.gov
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Disease (NIAID) is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Rapid Molecular
Assays for Specific Detection and Quantitation of Loa Loa
Microfilaremia. For collaboration opportunities, please contact Johanna
Schneider, PhD. at Schneiderjs@niaid.nih.gov or 301-451-9824.
Diagnostic Assays and Methods of Use for Detection of Filarial
Infection
Description of Technology: The effort targeting the mosquito borne
neglected tropical disease lymphatic filariasis for elimination through
mass drug administration by 2020 will require accurate, cost effective
methods for detecting early infections. The World Health Organization-
recommended immunochromatographic test detects adult Wuchereria
bancrofti (Wb) antigen in blood, but shows variable efficacy due to the
complex life cycle of the parasites and cross reactivity with other
organisms. This variability may hinder effective lymphatic filariasis
elimination efforts. This new technology improves available detection
methods through use of an isolated immunoreactive antigen, Wb123, from
infective stage larvae (L3) Wb; which results in specific detection
early in the infective cycle with reduced cross reactivity. This
technology may see wide application in testing and surveillance of
lymphatic filariasis as part of the effort to eliminate the disease
worldwide.
Potential Commercial Applications:
Diagnostics testing.
Infectious disease monitoring.
Competitive Advantages: Improved detection of early stage lymphatic
filariasis.
Development Stage:
Early-stage.
Pre-clinical.
Inventors: Doran Fink (NIAID), Joseph Kubofcik (NIAID), Peter
Burbelo (NIDCR), Thomas Nutman (NIAID).
Publications:
1. Senbagavalli P, et al. Heightened measures of immune complex and
complement function and immune complex-mediated granulocyte activation
in human lymphatic filariasis. Am J Trop Med Hyg. 2011 Jul;85(1):89-96.
[PMID 21734131]
2. Bennuru S, et al. Stage-specific proteomic expression patterns
of the human filarial parasite Brugia malayi and its endosymbiont
Wolbachia. Proc Natl Acad Sci USA. 2011 Jun;7;108 (23):9649-9654. [PMID
21606368].
3. Steel C, et al. PLoS One. Altered T cell memory and effector
cell development in chronic lymphatic filarial infection that is
independent of persistent parasite antigen. 2011 Apr 29;6(4):e19197.
[PMID 21559422].
4. Fink DL, et al. Toward molecular parasitologic diagnosis:
enhanced diagnostic sensitivity for filarial infections in mobile
populations. J Clin Microbiol. 2011 Jan;49(1):42-47. [PMID 20980560].
5. Bennuru S, et al. Elevated levels of plasma angiogenic factors
are associated with human lymphatic filarial infections. Am J Trop Med
Hyg. 2010 Oct;83(4):884-890. [PMID 20889885].
Intellectual Property: HHS Reference No. E-281-2010/0--U.S.
Application No. 61/410,239 filed 04 Nov 2010.
Related Technologies:
HHS Reference No. E-084-2010/0--PCT Application No. PCT/
US2011/023320 filed 01 Feb 2011.
HHS Reference No. E-014-2011/0--U.S. Application No. 61/
410,232 filed 04 Nov 2010.
Licensing Contact: Tedd Fenn; 301-435-5031; Tedd.Fenn@nih.gov.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Disease (NIAID) is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Diagnostic
Assays and Methods of Use for Detection of Filarial Infection. For
collaboration opportunities, please contact Johanna Schneider, Ph.D. at
Schneiderjs@niaid.nih.gov or 301-451-9824.
A System and Method for Detecting Untoward Events in Hospitals
Description of Technology: This invention is of potential benefit
to public health and patient care and can be commercially utilized by
medical centers, hospitals and commercial developers of hospital
information systems. It is basically a computer science based
technology that may provide the capability of detecting untoward events
such as patient crises, individual clinic adverse occurrences and
adverse reactions related to new medication lots and inconsistencies in
ordered and delivered patient medications and other treatments. The
technology is comprised of a dedicated computer server that executes
specially designed software with input data from a main hospital
information system and other relevant patient data sensors and systems.
The technology also includes design specifications for constructing a
``patient registration system'', an untoward event specification
catalogue, intelligent software for detecting untoward events, and a
report listing untoward alerts, as well as a light and sound panel
design for signaling untoward alerts. The preferred embodiment for this
technology is the NIH Clinical Center Clinical Research Informatics
System (CRIS) presently operational in the NIH Clinical Center in
Bethesda, Maryland.
Potential Commercial Applications: The technology can be
commercially utilized by medical centers, hospitals and commercial
developers of hospital information centers to improve patient medical
treatment and clinical outcome.
Competitive Advantages: The design of the system is novel and
practical. It fulfills and automates the need for a system and
methodology that predicts, detects and signals untoward patient events
and other untoward clinical events.
Development Stage: Prototype.
Inventors: James M. DeLeo and Patricia P. Sengstack (NIHCC).
Publications:
1. Heldt T, et al. Integrating Data, Models, and Reasoning in
Critical Care. Proceedings of the 28th IEEE EMBS Annual International
Conference, New
[[Page 61719]]
York City, USA, Aug 30-Sept 3, 2006, pp 350-353; doi 10.1109/
IEMBS.2006.259734.
2. Hripcsak G, et al. Mining complex clinical data for patient
safety research: a framework for event discovery. J Biomed Inform. 2003
Feb-Apr;36(1-2):120-130. [PMID 14552853].
3. Horsky J, et al. A framework for analyzing the cognitive
complexity of computer assisted clinical ordering. J Biomed Inform.
2003 Feb-Apr;36(1-2):4-22. [PMID 14552843].
Intellectual Property: HHS Reference No. E-227-2009/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov.
Dated: September 26, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-25730 Filed 10-4-11; 8:45 am]
BILLING CODE 4140-01-P
